BRUCE CHRISTENSEN: Open Payments
NPI 1770616054 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$581 in 25 payments from 14 companies in 2025. Trend: 2023 $280 · 2024 $240 · 2025 $581
Food & beverage: $581
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 4 | $100 |
| AstraZeneca Pharmaceuticals LP | 4 | $98 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $69 |
| Genentech USA, Inc. | 2 | $54 |
| ABBVIE INC. | 2 | $51 |
| JAZZ PHARMACEUTICALS INC. | 2 | $46 |
| TerSera Therapeutics LLC | 1 | $28 |
| Celgene Corporation | 1 | $23 |
| CSL Behring | 1 | $23 |
| Melinta Therapeutics, LLC | 1 | $21 |
Products named: RYBREVANT, LYNPARZA, ZEPZELCA, HYQVIA, DARZALEX, VONVENDI, Polivy, VENCLEXTA.
Industry payments across TX — which companies pay providers there.
